Innoviva Research and Development Expenses 2010-2024 | INVA

Innoviva research and development expenses from 2010 to 2024. Research and development expenses can be defined as an expense arising from studies and product development processes.
Innoviva Annual Research and Development Expenses
(Millions of US $)
2023 $34
2022 $41
2021 $1
2020 $2
2019 $
2018 $
2017 $1
2016 $1
2015 $3
2014 $7
2013 $9
2012 $8
2011 $104
2010 $75
2009 $78
Innoviva Quarterly Research and Development Expenses
(Millions of US $)
2024-06-30 $3
2024-03-31 $4
2023-12-31 $2
2023-09-30 $4
2023-06-30 $15
2023-03-31 $13
2022-12-31 $10
2022-09-30 $12
2022-06-30 $14
2022-03-31 $6
2021-12-31 $0
2021-09-30 $0
2021-06-30 $0
2021-03-31 $0
2020-12-31 $0
2020-09-30 $1
2020-06-30 $1
2020-03-31
2019-12-31
2019-09-30
2019-06-30
2019-03-31
2018-12-31
2018-09-30
2018-06-30
2018-03-31
2017-12-31 $0
2017-09-30 $0
2017-06-30 $0
2017-03-31 $0
2016-12-31 $0
2016-09-30 $0
2016-06-30 $0
2016-03-31 $0
2015-12-31 $1
2015-09-30 $1
2015-06-30 $1
2015-03-31 $1
2014-12-31 $1
2014-09-30 $2
2014-06-30 $2
2014-03-31 $3
2013-12-31 $-22
2013-09-30 $2
2013-06-30 $2
2013-03-31 $26
2012-12-31 $28
2012-09-30 $27
2012-06-30 $30
2012-03-31 $33
2011-12-31 $32
2011-09-30 $28
2011-06-30 $23
2011-03-31 $20
2010-12-31 $17
2010-09-30 $19
2010-06-30 $19
2010-03-31 $20
2009-12-31 $18
2009-09-30 $20
2009-06-30 $20
2009-03-31 $20
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $1.271B $0.310B
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $777.357B 80.52
Novo Nordisk (NVO) Denmark $480.435B 34.65
Johnson & Johnson (JNJ) United States $367.500B 14.91
AbbVie (ABBV) United States $302.340B 15.91
Merck (MRK) United States $249.371B 16.57
Novartis AG (NVS) Switzerland $214.456B 14.26
AstraZeneca (AZN) United Kingdom $202.127B 17.20
Pfizer (PFE) United States $148.418B 10.15
Sanofi (SNY) $127.247B 11.53